Clayton Russell has filed 6 insider transactions across 1 company since January 2024.
Most recent transaction: a grant/award of 25637 shares of Larimar Therapeutics, Inc. ($LRMR) on January 26, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 26, 2026 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Common Stock | 25637 | $0.00 | 71,443.0000 | 85,590,392 | 55.97% | 0.03% |
| Jan. 26, 2026 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Stock Option (Right to Buy) | 153822 | $0.00 | 153,822.0000 | 85,590,392 | 9999.99% | 0.18% |
| Jan. 22, 2025 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Common Stock | 23306 | $0.00 | 45,806.0000 | 63,815,065 | 103.58% | 0.04% |
| Jan. 22, 2025 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Stock Option (Right to Buy) | 139838 | $0.00 | 139,838.0000 | 63,815,065 | 9999.99% | 0.22% |
| Jan. 17, 2024 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Common Stock | 22500 | $0.00 | 22,500.0000 | 43,909,069 | 9999.99% | 0.05% |
| Jan. 17, 2024 | Larimar Therapeutics, Inc. | $LRMR | Clayton Russell | Chief Medical Officer | A | Stock Option (Right to Buy) | 135000 | $0.00 | 135,000.0000 | 43,909,069 | 9999.99% | 0.31% |